Free Trial

Hims & Hers Health (HIMS) Stock Price, News & Analysis

Hims & Hers Health logo
$49.94 +0.53 (+1.07%)
As of 06/30/2025 03:58 PM Eastern

About Hims & Hers Health Stock (NYSE:HIMS)

Key Stats

Today's Range
$48.33
$50.78
50-Day Range
$25.41
$64.47
52-Week Range
$13.47
$72.98
Volume
36.43 million shs
Average Volume
23.06 million shs
Market Capitalization
$11.18 billion
P/E Ratio
72.38
Dividend Yield
N/A
Price Target
$39.58
Consensus Rating
Reduce

Company Overview

Hims & Hers Health (NYSE: HIMS) is a telehealth company that operates a direct-to-consumer platform offering prescription and over-the-counter products across a range of wellness categories. Founded in 2017 by Andrew Dudum, the company initially targeted men’s sexual health and hair loss solutions before expanding its offerings in 2020 under the Hims & Hers umbrella. Customers access the platform via its website or mobile app, complete a virtual consultation with a licensed healthcare provider, and receive personalized treatment plans shipped directly to their door.

The company’s portfolio encompasses treatments for hair and skin care, sexual health, mental wellness and general health, as well as nutritional supplements and lifestyle products. Branded formulations include topical minoxidil for hair regrowth, prescription dermatology medications, and FDA-approved therapies for erectile dysfunction and birth control. In addition to medications, Hims & Hers features content and self-care tools designed to educate users on preventive health measures and overall well-being.

Hims & Hers serves primarily the U.S. market, with operations headquartered in San Francisco and satellite offices in New York and Austin. The company went public via a special purpose acquisition company (SPAC) merger in early 2021, positioning itself to accelerate growth through product innovation and geographic expansion. Its technology-driven approach aims to reduce barriers to care by integrating telehealth consultations with in-house pharmacy fulfillment and discreet shipping.

Under the leadership of founder and CEO Andrew Dudum, Hims & Hers has cultivated a multidisciplinary team of medical, regulatory and consumer-brand experts. The company continues to explore new markets and partnerships, leveraging data analytics and digital marketing to refine its product offerings and enhance the patient experience in an evolving virtual care landscape.

AI Generated. May Contain Errors.

Hims & Hers Health Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

HIMS MarketRank™: 

Hims & Hers Health scored higher than 42% of companies evaluated by MarketBeat, and ranked 693rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Hims & Hers Health has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on 2 buy ratings, 8 hold ratings, and 3 sell ratings.

  • Amount of Analyst Coverage

    Hims & Hers Health has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Hims & Hers Health's stock forecast and price target.
  • Earnings Growth

    Earnings for Hims & Hers Health are expected to grow by 79.31% in the coming year, from $0.29 to $0.52 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Hims & Hers Health is 72.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.77.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Hims & Hers Health is 72.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.44.

  • Price to Earnings Growth Ratio

    Hims & Hers Health has a PEG Ratio of 1.86. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Hims & Hers Health has a P/B Ratio of 23.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Hims & Hers Health's valuation and earnings.
  • Percentage of Shares Shorted

    31.94% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 1.33%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Hims & Hers Health does not currently pay a dividend.

  • Dividend Growth

    Hims & Hers Health does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    31.94% of the float of Hims & Hers Health has been sold short.
  • Short Interest Ratio / Days to Cover

    Hims & Hers Health has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Hims & Hers Health has recently increased by 1.33%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Hims & Hers Health has a news sentiment score of 0.10. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 97 news articles for Hims & Hers Health this week, compared to 25 articles on an average week.
  • Search Interest

    Only 181 people have searched for HIMS on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
  • MarketBeat Follows

    Only 57 people have added Hims & Hers Health to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Hims & Hers Health insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $35,130,249.00 in company stock.

  • Percentage Held by Insiders

    17.71% of the stock of Hims & Hers Health is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    63.52% of the stock of Hims & Hers Health is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Hims & Hers Health's insider trading history.
Receive HIMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.

HIMS Stock News Headlines

Hims & Hers telehealth and stock chart - This image is an original composition by MarketBeat using licensed and editorial elements. Not for redistribution or reuse.
Why Hims & Hers Stock Could Be a Multi-Bagger in the Making
Hims & Hers stock keeps giving investors more reasons to buy, and has all the right factors to turn it into a potential multi-bagger investment.
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

HIMS Stock Analysis - Frequently Asked Questions

Hims & Hers Health's stock was trading at $24.18 at the beginning of the year. Since then, HIMS stock has increased by 106.5% and is now trading at $49.94.
View the best growth stocks for 2025 here
.

Hims & Hers Health, Inc. (NYSE:HIMS) posted its earnings results on Monday, May, 5th. The company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.12 by $0.08. The business's revenue for the quarter was up 110.7% on a year-over-year basis.
Read the conference call transcript
.

Shares of HIMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Hims & Hers Health investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
5/05/2025
Today
7/01/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
MEDICAL INFO SYS
Sub-Industry
Healthcare
Current Symbol
NYSE:HIMS
Fax
N/A
Employees
1,637
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$39.58
High Stock Price Target
$68.00
Low Stock Price Target
$26.00
Potential Upside/Downside
-20.7%
Consensus Rating
Reduce
Rating Score (0-4)
1.92
Research Coverage
13 Analysts

Profitability

Trailing P/E Ratio
72.38
Forward P/E Ratio
172.21
P/E Growth
1.86
Net Income
$126.04 million
Pretax Margin
6.71%

Debt

Sales & Book Value

Annual Sales
$1.48 billion
Cash Flow
$0.36 per share
Price / Cash Flow
140.30
Book Value
$2.16 per share
Price / Book
23.12

Miscellaneous

Free Float
184,191,000
Market Cap
$11.18 billion
Optionable
Optionable
Beta
2.09
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NYSE:HIMS) was last updated on 7/1/2025 by MarketBeat.com Staff
From Our Partners